Trial Profile
Randomised, Double-blind, Placebo-controlled Parallel-group Proof of Mechanism Study to Assess the Pharmacokinetics and to Evaluate the Pharmacodynamic Effect of Different Single Oral Doses of BI 409306 in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Osoresnontrine (Primary)
- Indications Affective disorders; Anxiety disorders; Schizophrenia and disorders with psychotic features
- Focus Biomarker; Pharmacodynamics; Pharmacokinetics
- 06 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jan 2012 New trial record